ELDN · Eledon Pharmaceuticals, Inc. · Metrics
$2.62
+0.00 (+0.00%)
At close · Nov 3
Return incl. dividend (before tax)
Q1 2023 earnings call transcript
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's current operating plan, the Company expects that, within the next twelve months, its existing cash, cash equivalents, short-term investments and other available resources will not be sufficient to fund its planned operations and satisfy its obligations as they become due unless it obtains additional financing. Based on these conditions and events that are known and reasonably knowable as of the date these condensed consolidated financial statements are issued, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Although management intends to obtain additional financing through the sources described above, these plans are subject to market conditions and other factors outside the Company's control. Accordingly, management has concluded that its plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$212.90M
Shares
81.26M
Volume · Nov 3
403.17K
Avg daily vol (3M)
913.96K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
ELDN metrics
58 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$2.62
Market cap
$212.90M
Price action
20 metricsPrice change (1W)
+18.6%
Price change (30D)
+4.8%
Price change (3M)
-23.6%
Price change (6M)
-30.7%
Price change (YTD)
+73.5%
Price change (1Y)
-39.4%
Trailing year
Price change (5Y)
-48.3%
52-week high
$4.36
52-week low
$1.39
Change from 52-week high
-39.9%
Change from 52-week low
+88.5%
Annualized volatility
84.6%
Annualized volatility (3M)
62.7%
Beta
1.9
RSI (14D)
52.7
Price vs SMA 50
-1.8%
Price vs SMA 200
-15.7%
Avg volume (3M)
932,387
Relative volume
0.7
Average dollar volume
$2.72M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
81.26M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
6.4
reciprocal yield 15.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-46.3%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-06-22
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$56.22M
Net income (TTM)
−$98.56M
Trailing 12 months
Diluted EPS (TTM)
$-0.91
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+47.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-298.6%
Return on assets
-78.2%
Debt / equity
0.0
Current ratio
7.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
7.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$88.76M
Latest balance sheet
Cash & equivalents
$6.80M
Total assets
$126.09M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$73.86M
Capital expenditures (TTM)
—
R&D (TTM)
$67.89M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
161
13F filer change QoQ
+38
Institutional ownership
58.8%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
20.9%
Private-fund adviser ownership
19.6%
Active holders' share change QoQ
-0.1%
Holder tenure
10.1
Price vs estimated holder cost
+14.1%
Ownership (registered funds)
1 metricsIndex-fund ownership
11.5%
Short interest
3 metricsShort interest
9.7%
Latest settlement · 10.3 days to cover
Days to cover
10.3d
Short-squeeze score
73 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged
Key facts
CIK
1404281
CUSIP
28617K101
13F (30d)
45 filings
44 filers
Visit website
Investor relations